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A Systematic Review of Quality of Life Associated with
Standard Chemotherapy Regimens for Advanced
Non-small Cell Lung Cancer
Tawee Tanvetyanon, MD, Heloisa P. Soares, MD, Benjamin Djulbegovic, MD, PhD,
Paul B. Jacobsen, PhD, and Gerold Bepler, MD, PhD
Purpose: Systemic chemotherapy is accepted as a standard of care
for patients with advanced non-small cell lung cancer (NSCLC).
Although survival outcomes are equivalent among standard chemo-
therapy regimens, it is unknown whether the quality of life (QOL)
outcomes are also comparable. We evaluated available literatures to
summarize the state of current knowledge and provide suggestions
for future studies.
Methods: Using PUBMED/MEDLINE database, a systematic re-
view of randomized controlled phase III trials of advanced NSCLC
reporting QOL as one of the end points was conducted. Trials were
included if standard chemotherapy regimens (as defined by The
American Society of Clinical Oncology 2003 recommendations)
were used in at least two arms of a trial. Two reviewers indepen-
dently extracted data and evaluated the characteristics of QOL
reporting, analyses, and results.
Results: The search criteria identified 14 trials (6665 patients). Of
these, 13 trials used validated QOL instruments and were included
for review. The QOL reporting/analysis techniques were heteroge-
neous. We included nine trials, which reported the rate of completed
baseline assessment and compliance survivors at analysis greater
than 50%, for data synthesis. Of these, only one trial found a
significant difference in QOL between the comparator arms: pacli-
taxel plus cisplatin was better than teniposide plus cisplatin.
Conclusion: Based on our review, it seems unlikely that a major
difference exists in the global QOL associated with standard che-
motherapy regimens for advanced NSCLC. Although QOL report-
ing format is largely acceptable, a lack of uniformity in analysis and
a poor compliance to QOL assessment made between-trial compar-
isons difficult.
Key Words: Quality of life, Non-small cell lung cancer, Chemo-
therapy, Systematic review.
(J Thorac Oncol. 2007;2: 1091–1097)
For patients with advanced non-small cell lung cancer(NSCLC) who have a good performance status (2 or
better), systemic chemotherapy is the current standard of
care. When compared with best supportive care alone, chemo-
therapy significantly improves survival and, potentially, quality
of life (QOL).1,2 The American Society of Clinical Oncology
(ASCO) has recommended that first-line chemotherapy should
be a two-drug regimen. Non–platinum-containing chemotherapy
regimens may be used as alternatives to platinum-based regi-
mens in the first-line setting.3 In terms of survival efficacy,
numerous phase III trials conducted during the past decade have
not identified any superior combination.
Because of the relative equivalence of these treatment
options, some authors have investigated other important out-
come parameters, such as economics, to help clinicians
choose a preferred regimen.4 QOL is also an important
outcome parameter and may be useful to guide treatment
choice. A recent review of the literature including all stages
and phases of NSCLC studies published up to 2002 indicated
that there were methodological problems with QOL reporting
and only approximately 60% of assessed trials were of
acceptable quality.5 Because of these problems, the QOL
results have never been critically evaluated. Since then, a
panel of experts has developed a checklist to enable a rapid
and objective assessment of QOL reporting.6,7 Many QOL
instruments have been developed and refined, and a growing
number of phase III trials have incorporated QOL measure-
ments. It is possible that the QOL methodology and reporting
format, especially among phase III studies, may have im-
proved to the level that a meaningful synthesis of data can be
conducted. To date, QOL outcomes of standard chemother-
apy (definition as per 2003 ASCO recommendations) for
advanced NSCLC (i.e., stage IIIB or IV) have not been
systematically reviewed.
The objective of this review was to understand the
characteristics of reporting formats, analysis methods, and the
results of QOL from clinical trials investigating standard
chemotherapy regimens for advanced NSCLC. We attempted
to compare the QOL outcomes among standard chemother-
apy regimens to summarize the state of current knowledge
and provide guidance for future improvement. In addition,
although QOL is dependent on several factors, treatment-
related toxicity can be a major contribution to a change in
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QOL.8 We therefore briefly reviewed the toxicities associated
with these regimens along with QOL outcomes.
METHODS
Eligibility Criteria
We included randomized controlled phase III studies
that investigated efficacy and QOL of first-line chemotherapy
in advanced stage IIIB and/or stage IV NSCLC. Eligible trials
had to use a standard chemotherapy, defined as a platinum-
containing doublet or a non-platinum doublet with newer
agents as outlined in the 2003 ASCO recommendations, in at
least two arms of the study. For the purpose of this review, we
included the regimens with platinum plus vindesine, etopo-
side, or teniposide. If the trial included three or more arms
and at least two arms met the inclusion criteria, these two
arms were selected for analysis, and the remaining arms were
excluded. Trials that exclusively enrolled an elderly popula-
tion (older than 70 years) or patients with performance status
2 were excluded.
Identification of Trials
Two reviewers independently searched the PUBMED/
MEDLINE database (January 1966 to May 2006) using the
following search strategy: (1) lung cancer and quality of life and
(metastatic or advanced) AND (2) clinical(title/abstract) AND
(3) trial (title/abstract) OR (4) clinical trials (MeSH terms) OR
(5) clinical trial (publication type) OR (6) random * (title/ab-
stract) OR (7) random allocation (MeSH terms) OR (8) thera-
peutic use (MeSH subheading). The search was limited to
English publications. Titles and abstracts from the PUBMED
database were reviewed with full-text copies of all studies of
possible relevance. The bibliography of relevant articles was
also screened. During a consensus meeting, the reviewers de-
cided which studies met the inclusion criteria for the review.
Duplicative publications were only included for data extraction
if they added additional information to the chosen publication
cited in the review.
Data Collection
The following information was collected from the identi-
fied trials: year of publication, QOL instrument used, QOL
methodology, total number of patients, number of patients as-
sessed for QOL outcomes, toxicity criteria used, percentage of
patients with febrile neutropenia and toxic death, number of
patients assessable for response, tumor response rate (complete
response plus partial response), number of patients assessable
for survival, median survival time, and 1-year survival.
Evaluating the QOL Conducts and Results
To assess the methodological and reporting character-
istics of the eligible trials, we used an 11-item checklist for
evaluating QOL outcomes in cancer clinical trials developed
by an expert consensus (Table 1).5 For the purpose of this
review, trials that reported patient compliance to QOL as-
sessment at baseline and at subsequent assessment intervals
were allowed on the criterion “Missing data documented.”
Two reviewers independently assessed each trial, and dis-
crepancies were resolved by consensus. Only trials that used
validated QOL instruments, i.e., tested adequately for psy-
chometric reliability and cultural validity as previously re-
viewed and without subsequent modification, were re-
viewed.5 For data synthesis, to ascertain validity of data, we
selected the trials with a completed baseline assessment rate
and a compliance rate to assessment among survivors at the
analysis point greater than 50%. In addition, trials with only
a single assessment in QOL without baseline assessment were
excluded from data synthesis.
RESULTS
Identification of Trials and General
Characteristics of the Trials
We identified 14 studies contributing to 18 pair-wise
comparisons. There were four studies that contained three
arms; all pairs were analyzed separately (Table 2). The
characteristics and results of these 14 trials have been indi-
vidually reported.9–23 In brief, a total of 6665 patients were
enrolled. The dosage and intensity of chemotherapy regimens
were largely consistent with standard practice, except for one
TABLE 1. Checklist for Evaluating QOL Reportinga
QOL Reporting
Characteristics Description
A priori hypothesis
stated
Assessed whether authors had a
predefined QOL end point and/or stated
expected changes because of the
specific treatment
Rationale for
instrument reported
Assessed whether authors gave a rationale
for using a specific QOL measure
Psychometric
properties reported
Assessed whether a previously validated
measure was used
Cultural validity
verified
Assessed whether the measure was
validated for the specific study
population or whether the QOL
measure was validated in the same
population as the one in the trial
Adequacy of domains
covered
Assessed whether the measure covered, at
least, the main dimensions relevant for
NSCLC and/or according to the specific
research question
Instrument
administration
reported
Assessed whether authors specified for
whom and/or in which clinical setting
the QOL instrument was administered
Baseline compliance
reported
Assessed whether authors reported the
number of patients providing QOL
assessment before the start of treatment
Timing of assessments
documented
Assessed whether authors specified the
QOL timing of assessment during the
trial
Missing data
documented
Assessed whether authors provided details
on QOL missing data during the trial
Clinical significance
addressed
QOL data were clinically significant from
a patient’s perspective and not simply
statistically significant
Presentation of results
in general
Assessed whether authors discussed the
QOL outcomes, giving any comments
regardless of the results
QOL, quality of life; NSCLC, non-small cell lung cancer.
aAdapted from Reference 7.
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trial in which 24-hour infusional paclitaxel was used.22 The
overall tumor response rate in these trials ranged from 12% to
46%; 1-year survival ranged from 26% to 48%, and median
survival ranged from 6.7 to 11.3 months. In four tri-
als,14,17,19,23 a statistically significant difference in the overall
survival between the comparator arms was reported.
Characteristics of QOL Reporting
The characteristics of QOL reporting based on the 11-item
checklist are shown in Table 2. Most (12 of 14 [86%]) had a
robust QOL report according to the criteria. One study met all 11
criteria. With regard to the “priori hypothesis stated” criterion,
two trials seemed to use QOL as primary end point, but in one
trial, the QOL data were not collected until halfway into the
study and thus not considered as priori.20,21 All trials used
instruments that were tested for reliability and validated in the
countries of patient accrual, such as EORTC QLQ C30 or
FACT-L, but in one trial, the EORTC QLQ C30 instrument was
modified and we could not confirm that the modified version
was validated.13 Investigators also frequently chose to integrate
a lung cancer module, providing adequate domain coverage for
patients with lung cancer.
Characteristics of QOL Conduct
Selected characteristics of QOL are shown in Table 3.
EORTC QLQ C30 LC-13 was the most commonly used instru-
ment (eight trials), followed by FACT-L (three trials). One trial
used two QOL instruments. The reported percentage of patients
who completed baseline QOL assessment ranged from 49% to
94%. The planned number of QOL measurements during che-
motherapy and interval of assessment varied greatly. Three trials
did not specify the number, and one trial only measured QOL
once. Among trials that specified the planned number of QOL
assessments, three trials planned to measure QOL beyond 18
weeks from the initiation of chemotherapy. The percentage of
patients that completed the assessment varied from 49% to 95%
at baseline and 26% to 90% at the time of QOL analysis. Two
studies did not report the rate of compliance at baseline, and one
did not state whether QOL evaluation was required at baseline.
The total number of QOL assessments also varied, ranging from
one to seven.
QOL Analyses
The method of QOL analysis and reporting is heteroge-
neous. The primary QOL variable used in the trials varied. In
particular, six studies used a change in QOL score from baseline
at each assessment interval, three simply used the raw score, two
converted the score into a new variable before analysis, and one
adjusted the score for baseline of the group before analysis. In
addition, the time point at which variables were taken into
analysis varied, ranging from 6 weeks into therapy to 12 weeks
after completion of therapy. Finally, in the four trials with three
treatment arms, three trials made two comparisons separately
between the two experimental arms versus a control arm; one
trial directly compared all three arms.
QOL Results
To ensure the validity of QOL results, we selected trials
with a compliance rate to baseline assessment and at analysis
points among survivors greater than 50% for data synthesis.TA
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This left nine trials for further review (Table 4). Most trials
reported no significant differences between comparator arms.
Only one study found a significant difference between com-
parator arms: paclitaxel plus cisplatin was superior to teni-
poside plus cisplatin. In trials that reported no difference in
global QOL between arms, a significant difference was some-
times reported in selected domains of the QOL as detailed in
Table 4. For instance, in the study by Gridelli et al.,16 more
anorexia, fatigue, and nausea or vomiting were found in the
platinum-containing arm than in the gemcitabine plus vi-
norelbine arm.
We also looked into the change in QOL over time.
There was either minimal or no change in QOL over time in
these trials. Four trials provided a graph demonstrating the
change in global QOL over time. Gridelli et al.16 and Smit et
al.15 respectively reported that 9 weeks after treatment and at
the end of the sixth cycle, the mean changes from baseline in
QOL measured by EORTC QLQ-C30 were minimal. Using
LCSS, Fossella et al. 17 also reported a change in score fewer
than 5 points from baseline at 18 weeks in both arms. Finally,
Kubota et al. 14 reported a minimal change in global QOL
score from baseline.
Characteristics of Toxicity Reports and Results
To understand the difference in QOL outcomes, we
reviewed selected toxicity profiles reported in these trials
(Table 4). Most trials did not report the number of patients
who discontinued therapy because of toxicity. One study did
not specify the toxicity criteria.19 The incidence of treatment-
related mortality ranged from 0% to 7.6%. We were unable to
find a single consistent toxicity that would predict global
QOL outcomes. In the one trial that showed a significant
difference in the global QOL, the incidences of grade 3 and
4 neutropenia seemed to be higher in the arm associated with
TABLE 4. QOL and Toxicity Results Among Trials with Compliance to QOL Assessments of At Least 50%
Reference Regimen
Global QOL results
(p value)
Comments, Difference of
QOL in Relevant
Domains
Report
Discontinued
Patients for
Safety
Treatment-related
Mortality (%)
Neutropenic
Fever
(%)
Grade 3, 4
Neutropenia
(%)
Pujol et al.9 D/G
V/Ci
No significant difference None Yes 2.6
5.1
8
22
52
83
Georgoulias et al.10 D/G
V/Ci
No significant difference
(p not reported)
More improvement of
hemoptysis and pain
from baseline in D/G, but
not in V/Ci
No 2.5
3.1
6
11
17
37
Cardenal
et al.11
G/Ci
E/Ci
No significant
difference (p not
reported)
None No 1.0
0
7
12
64
76
Kubota
et al.14
D/Ci
Vin/Ci
No significant difference
(p not reported)
The difference only reached
statistical significant for
the functional domain
No 1.3
0
NR 39
27
Gridelli
et al.16
V/Ci or
G/Ci
G/V
No significant difference
(p  0.94)
More anorexia, fatigue,
nausea or vomiting,
alopecia in V/Ci or G/Ci
Yes 4.4
2.8
NR 32
14
Scagliotti
et al.18
G/Ci
P/Ca
V/Ci
No significant
differences in both
comparisons (p not
reported)
For G/Ci vs. V/Ci: more
neuropathy in V/Ci; for
P/Ca vs. V/Ci: more
nausea or vomiting,
anorexia, fatigue in V/
CiMore pain, alopecia,
neuropathy in P/Ca
No 4.1
1.5
3.5
1
1
3
38
50
65
Rosell
et al.19
P/Ci
P/Ca
No significant difference
(p  0.93)
More anorexia in P/CiMore
pain, chest pain,
hemoptysis in P/Ca
No 7.6
5.6
1
2
51
54
Bonomi
et al.22
E/Ci
P/Ci
P/Ci
For 3-arm comparison:
No significant
difference (p  0.45
for TOI and 0.59 for
FACT-L); for E/Ci
and the other two
arms with P: No
significant difference
(p  0.46)
There was a significantly
higher proportion of
patients with an
improved TOI score in
the arms with P, when
including patient with
missing data in the
analysis (p  0.01)
No NAa NAa 28
19
21
Giaccone et al.23 T/Ci
P/Ci
T/Ci worse (p  0.002) None No 3.7
1.9
2
7
3
81
54
NR, not reported; NA, not available; QOL, quality of life; P, paclitaxel; Ci, cisplatin; G, gemcitabine; Ca, carboplatin; V, vinorelbine; D, docetaxel; ORR, overall response rate.
a Reported as a total toxic death in three arms (10 patients [1.7%]), and the total percentage of patients with neutropenic fever was 9%.
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inferior QOL.23 However, in other trials, in which there
seemed to be a difference in this side effect, no significant
difference in global QOL was observed.
DISCUSSION
The main objective of this review was to understand
whether the QOL and toxicity outcomes from standard,
first-line chemotherapy for NSCLC are equivalent. We began
by ascertaining the quality of QOL reporting of the identified
trials. Of 14 included trials, only 9 were of acceptable quality,
as demonstrated by at least 50% of surviving patients being
complaint to baseline assessment and to the assessment at one
subsequent analysis point. We were unable to perform a
meta-analysis on QOL outcomes because of the marked
heterogeneity of the analysis and reporting format among
these trials. Only one of the nine trials reported a significant
difference between the comparator arms.
Compared with previous reviews of QOL methodology
in NSCLC, it seems that the quality of QOL reporting in these
phase-III trials has much improved. A previous review of
phase II and early-stage lung cancer trials found that more
than 30% of trials did not test for statistical significance of
QOL change, whereas all of our included trials did.5 Previ-
ously, the baseline compliance was reported as mandatory in
only 14% of trials, whereas in the present review, it was
reported as mandatory in 13 of 14 trials. In 1998, another
review on QOL in NSCLC found eight trials with a random-
ized design that reported on QOL outcomes.24 Only three of
eight trials used a QOL instrument adequately covering
domains for patients with lung cancer, whereas in the current
review, 12 of 14 trials did. Despite this improvement, there is
still a great heterogeneity in the analysis and reporting format
and a large number of non-compliance resulting in missing
data. Most studies did not report the values of the primary
QOL outcome variable, making it difficult to compare the
magnitude of difference among trials.
Based on our review, toxicities may not always lead to
an inferior global QOL. Previous systematic review indicated
that platinum-containing regimens (cisplatin or carboplatin)
were modestly associated with increased toxicities.25–27 In
our review, we did not find any difference between platinum-
and non–platinum-containing regimens with regard to QOL
outcome.9,10,16 Ones may suspect that first-generation plati-
num-containing regimens are associated with more toxicities
and less QOL than their second-generation counterparts,
based on the finding that teniposide plus cisplatin was asso-
ciated with more toxicities and less QOL than paclitaxel plus
cisplatin.23 However, another first-generation platinum dou-
blet, etoposide plus cisplatin, despite associated with an
increased risk of neutropenic fever, had a QOL outcomes
comparable to those resulted from a second-generation plat-
inum doublet, gemcitabine plus cisplatin.11 It is possible that
each chemotherapy regimen has its advantages and disadvan-
tages in terms of side effect profiles, therefore balancing the
global QOL score.
A number of recommendations can be made regarding
QOL conduct and reporting. First, an effective way to im-
prove the compliance in QOL assessment is needed. For
advanced NSCLC, missing data resulting from death and
withdraw from study is an inherent problem,28 but such
decreased number of patients at subsequent assessments can
render any difference, if it exists, statistically insignificant.
Second, future trials that plan to collect QOL data should
follow a similar format of analysis and reporting as previ-
ously reported trials using a similar chemotherapy regimen to
facilitate comparison. Third, it is important to report the
magnitude of changes in the QOL end points used for
analysis. In many of the reviewed trials, only p values were
reported, making it difficult to understand the clinical rele-
vance of the difference or the lack of difference in QOL
outcomes. A statistically significant difference may not be
clinically relevant. For instance, in EORTC QLQ-C30, a
score change of 10 is considered a clinical significance
threshold. Both Gridelli et al.16 and Smit et al.15 found a
change of less than 10 points in global QOL from baseline in
both arms at the final QOL assessment.29 For FACT-L, a 5-
to 7-point change in Trial Outcome Index score is necessary
to make a minimal clinical impact for patients.30
Our review has a number of limitations. First, most of
the trials measured QOL for only a few months during
treatment, which does not necessarily reflect what happens to
patients afterward. Some side effects associated with specific
chemotherapy regimens may be reversible; others continue to
persist for most of the patient’s life. Second, the trials
selected for review represent a group of trials that report QOL
outcomes. The findings regarding QOL outcomes or toxici-
ties may not necessarily be generalizable to all other chemo-
therapy regimens for advanced NSCLC. Third, there is still
no standard tool to assess QOL reporting methodology.
Although several comprehensive measures are available,31,32
more stringent criteria would have further limited eligible
studies, thus making any conclusion less generalizable. Fi-
nally, various QOL instruments differ quite substantially in
the content and question phrasing.33 Caution should be exer-
cised when interpreting results obtained from different instru-
ments, especially if they are to be used in the context of a
different population.
In conclusion, we found that there is an improvement in
the QOL research in NSCLC, although there is a room for
improvement, particularly in regard to the uniformity of
analysis and compliance to QOL assessment. Toxicity report-
ing, including TRM and patient discontinuation because of
safety, is also suboptimal as per the CONSORT statement.34
Global QOL associated with standard chemotherapy regi-
mens seems to be largely comparable. Based on this review,
it is unlikely that a major difference exists in the global QOL
associated with standard chemotherapy regimens.
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